CVS Caremark has granted preferred formulary status to both Novo Nordisk’s (CPSE: NOVO B) Wegovy and Eli Lilly’s Zepbound and Foundayo, reversing Wegovy’s prior commercial advantage.
The decision levels the competitive playing field among GLP-1 obesity drug treatments within CVS Caremark’s pharmacy benefit network.
Previously, Wegovy held a distinct formulary edge over competing GLP-1 therapies, giving Novo Nordisk a measurable commercial advantage within this major benefit manager’s coverage.
The shift means access and competitive positioning for GLP-1 obesity therapies across CVS Caremark’s network will no longer favor any single treatment over another.
For investors, the removal of Wegovy’s preferred status places greater emphasis on real-world outcomes, physician preference, and broader payer decisions as competitive differentiators.
How other pharmacy benefit managers respond to this change may serve as an important reference point when assessing Novo Nordisk’s standing in the obesity treatment segment.
Prescription share trends within major pharmacy benefit managers, pricing or rebate changes, and commentary on GLP-1 volumes in upcoming earnings results could offer clues about the financial impact.
On valuation, the stock is described as trading 55.1% below its estimated fair value, representing a sizeable gap that some investors may view as an opportunity despite the formulary setback.
At DKK292.95, the share price sits approximately 5.5% below the analyst consensus target of DKK309.95, broadly in line with market expectations.
Novo Nordisk’s share price has risen 14.6% over the last 30 days, reflecting strong short-term investor interest even as the competitive landscape shifts.
Analysts have flagged a high level of debt and earnings quality concerns tied to non-cash items, factors investors may want to weigh alongside the GLP-1 growth opportunity.
The CVS Caremark decision shifts the broader narrative around Novo Nordisk toward how effectively the company can compete on clinical outcomes, patient access, and prescriber loyalty rather than formulary exclusivity.
